Kristen Pettit1, Olatoyosi Odenike2. 1. Section of Hematology/Oncology, Department of Medicine, The University of Chicago, 5841 S. Maryland Ave, MC2115, Chicago, IL, 60637, USA. 2. Section of Hematology/Oncology, Department of Medicine, The University of Chicago, 5841 S. Maryland Ave, MC2115, Chicago, IL, 60637, USA. todenike@medicine.bsd.uchicago.edu.
Abstract
PURPOSE OF REVIEW: The purpose of the review was to provide a contemporary update of novel agents and targets under investigation in myelofibrosis in the Janus kinase (JAK) inhibitor era. RECENT FINDINGS: Myelofibrosis (MF) is a clonal stem cell disease characterized by marrow fibrosis and a heterogeneous disease phenotype with a variable degree of splenomegaly, cytopenias, and constitutional symptoms that significantly impact quality of life and survival. Overactive JAK/STAT signaling is a hallmark of MF. The only approved therapy for MF, JAK1/2 inhibitor ruxolitinib, can ameliorate splenomegaly, improve symptoms, and prolong survival in some patients. Therapeutic challenges remain, however. Myelosuppression limits the use of ruxolitinib in some patients, eventual drug resistance is common, and the underlying malignant clone persists despite therapy. A deeper understanding of the pathogenesis of MF has informed the development of additional agents. Promising targets under investigation include JAK1 and JAK2 and downstream intermediates in related signaling pathways, epigenetic modifiers, pro-inflammatory cytokines, and immune regulators.
PURPOSE OF REVIEW: The purpose of the review was to provide a contemporary update of novel agents and targets under investigation in myelofibrosis in the Janus kinase (JAK) inhibitor era. RECENT FINDINGS:Myelofibrosis (MF) is a clonal stem cell disease characterized by marrow fibrosis and a heterogeneous disease phenotype with a variable degree of splenomegaly, cytopenias, and constitutional symptoms that significantly impact quality of life and survival. Overactive JAK/STAT signaling is a hallmark of MF. The only approved therapy for MF, JAK1/2 inhibitor ruxolitinib, can ameliorate splenomegaly, improve symptoms, and prolong survival in some patients. Therapeutic challenges remain, however. Myelosuppression limits the use of ruxolitinib in some patients, eventual drug resistance is common, and the underlying malignant clone persists despite therapy. A deeper understanding of the pathogenesis of MF has informed the development of additional agents. Promising targets under investigation include JAK1 and JAK2 and downstream intermediates in related signaling pathways, epigenetic modifiers, pro-inflammatory cytokines, and immune regulators.
Entities:
Keywords:
Drug development; JAK inhibitors; Myelofibrosis; Myeloproliferative neoplasms; Novel therapies
Authors: Claire Harrison; Jean-Jacques Kiladjian; Haifa Kathrin Al-Ali; Heinz Gisslinger; Roger Waltzman; Viktoriya Stalbovskaya; Mari McQuitty; Deborah S Hunter; Richard Levy; Laurent Knoops; Francisco Cervantes; Alessandro M Vannucchi; Tiziano Barbui; Giovanni Barosi Journal: N Engl J Med Date: 2012-03-01 Impact factor: 91.245
Authors: Matthew S Davids; Haesook T Kim; Pavan Bachireddy; Caitlin Costello; Rebecca Liguori; Alexandra Savell; Alexander P Lukez; David Avigan; Yi-Bin Chen; Peter McSweeney; Nicole R LeBoeuf; Michael S Rooney; Michaela Bowden; Chensheng W Zhou; Scott R Granter; Jason L Hornick; Scott J Rodig; Masahiro Hirakawa; Mariano Severgnini; F Stephen Hodi; Catherine J Wu; Vincent T Ho; Corey Cutler; John Koreth; Edwin P Alyea; Joseph H Antin; Philippe Armand; Howard Streicher; Edward D Ball; Jerome Ritz; Asad Bashey; Robert J Soiffer Journal: N Engl J Med Date: 2016-07-14 Impact factor: 91.245
Authors: John O Mascarenhas; Moshe Talpaz; Vikas Gupta; Lynda M Foltz; Michael R Savona; Ronald Paquette; A Robert Turner; Paul Coughlin; Elliott Winton; Timothy C Burn; Peter O'Neill; Jason Clark; Deborah Hunter; Albert Assad; Ronald Hoffman; Srdan Verstovsek Journal: Haematologica Date: 2016-10-27 Impact factor: 9.941
Authors: J A McCubrey; L S Steelman; S L Abrams; F E Bertrand; D E Ludwig; J Bäsecke; M Libra; F Stivala; M Milella; A Tafuri; P Lunghi; A Bonati; A M Martelli Journal: Leukemia Date: 2008-03-13 Impact factor: 11.528
Authors: John Mascarenhas; Lonette Sandy; Min Lu; James Yoon; Bruce Petersen; David Zhang; Fei Ye; Carrie Newsom; Vesna Najfeld; Tsivia Hochman; Judith D Goldberg; Ronald Hoffman Journal: Leuk Res Date: 2016-11-30 Impact factor: 3.156
Authors: C N Harrison; A M Vannucchi; J-J Kiladjian; H K Al-Ali; H Gisslinger; L Knoops; F Cervantes; M M Jones; K Sun; M McQuitty; V Stalbovskaya; P Gopalakrishna; T Barbui Journal: Leukemia Date: 2016-05-23 Impact factor: 11.528